Cited by 324Diabetes Management and ResearchDiabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Comparison of Insulin Regimens in Patients with Non-Insulin-Dependent Diabetes Mellitus

Open access

Yki-Järvinen, Hannele, Kauppila, Marjut, Kujansuu, Eila, Lahti, Jorma, Marjanen, Tapani, Niskanen, Leo, Rajala, Sulo, Ryysy, Leena, Salo, Seppo, Seppälä, Pentti, Tulokas, Timo, Viikari, Jorma, Karjalainen, Jukka, Taskinen, Marja-Riitta·1992·New England Journal of Medicine

DOI 10.1056/nejm199211123272005

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Insulin is widely used to improve metabolic control in patients with non-insulin-dependent diabetes mellitus (NIDDM), but there is no consensus about the optimal regimen of insulin treatment. METHODS: We treated 153 patients with NIDDM for three months with five regimens: (1) oral hypoglycemic drug therapy plus NPH insulin given at 7 a.m. (the morning-NPH group), (2) oral hypoglycemic drug therapy plus NPH insulin given at 9 p.m. (the evening-NPH group), (3) NPH and regular insulin (ratio, 70 units to 30 units) given before breakfast and dinner (the two-insulin-injection group), (4) NPH insulin at 9 p.m. and regular insulin before meals (the multiple-insulin-injection group), and (5) continued oral hypoglycemic drug therapy (the control group). RESULTS: The mean (+/- SE) value for glycosylated hemoglobin decreased similarly in all four insulin-treatment groups (1.7 +/- 0.3, 1.9 +/- 0.2, 1.8 +/- 0.3, and 1.6 +/- 0.3 percent, respectively). The decrease was significantly greater in these four groups than in the control group (0.5 +/- 0.2 percent; P < 0.001 vs. all insulin-treated groups). Weight gain was significantly less (1.2 +/- 0.5 kg) in the evening-NPH group than in the other insulin-treatment groups (2.2 +/- 0.5 kg in the morning-NPH group, 1.8 +/- 0.5 kg in the two-insulin-injection group, and 2.9 +/- 0.5 kg in the multiple-injection group; P < 0.05). In addition, the increment in the mean diurnal serum free insulin concentration was 50 to 65 percent smaller in the evening-NPH group than in the other insulin-treatment groups. Subjective well-being improved significantly more in the insulin-treatment groups than in the control group (P < 0.001). CONCLUSIONS: In patients with NIDDM who are receiving oral hypoglycemic drug therapy, the addition of NPH insulin in the evening improves glycemic control in a manner similar to combination therapy with NPH insulin in the morning, a two-insulin-injection regimen, or a multiple-insulin-injection regimen, but induces less weight gain and hyperinsulinemia. The data thus suggest that patients with NIDDM do not benefit from multiple insulin injections and that nocturnal insulin administration appears preferable to daytime administration.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm199211123272005

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

BMDP Statistical Software 1981.
Bubolz, T. A., & Dixon, W. J. (1984) · Journal of the American Statistical Association · doi:10.2307/2288308 · Cited by 5,231
Minimization: A new method of assigning patients to treatment and control groups
Taves, D. R. (1974) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1974155443 · Cited by 891
Determination of Free and Total Insulin and C-Peptide in Insulin-treated Diabetics
Kuzuya, H., BLIX, P. M., Horwitz, D. L., Steiner, D. F., & Rubenstein, A. H. (1977) · Diabetes · doi:10.2337/diab.26.1.22 · Cited by 603
DIABETES INCIDENCE IN PIMA INDIANS: CONTRIBUTIONS OF OBESITY AND PARENTAL DIABETES1
KNOWLER, W. C., PETTITT, D. J., SAVAGE, P. J., & BENNETT, P. H. (1981) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113079 · Cited by 561
Oral Hypoglycemic Agents
Oates, J. A., Wood, A. J. J., & Gerich, J. E. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911023211805 · Cited by 477
Postprandial hyperglycemia in patients with noninsulin-dependent diabetes mellitus. Role of hepatic and extrahepatic tissues.
Firth, R. G., Bell, P. M., Marsh, H. W., Hansen, I., & Rizza, R. A. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112467 · Cited by 284
Absorption Kinetics and Biologic Effects of Subcutaneously Injected Insulin Preparations
Berger, M., Cüppers, H. J., Hegner, H., Jörgens, V., & Berchtold, P. (1982) · Diabetes Care · doi:10.2337/diacare.5.2.77 · Cited by 249
Insulin Therapy in Obese, Non-insulin-dependent Diabetes Induces Improvements in Insulin Action and Secretion that Are Maintained for Two Weeks After Insulin Withdrawal
Andrews, W. J., Vasquez, B., NAGULESPARAN, M., Klimeś, I., Foley, J. E., Unger, R. H., & Reaven, G. M. (1984) · Diabetes · doi:10.2337/diab.33.7.634 · Cited by 194
Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes.
Taskinen, M., Kuusi, T., Helve, E., Nikkilä, E. A., & Yki‐Järvinen, H. (1988) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.8.2.168 · Cited by 184
Self-citation
Determination of free and total insulin and C-peptide in insulin-treated diabetics
Kuzuya, H., BLIX, P. M., Horwitz, D. L., et al. (1977) · Diabetes · doi:10.2337/diabetes.26.1.22 · Cited by 170

Show all 29 references

Research works printed but not linked: 2

Dixon WJ, ed. BMDP statistical software. Berkeley: University of California Press, 1983.
Hamilton, 1990, Am J Kidney Dis, 16, 20

Sorted by citations

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes Mellitus<SUBTITLE>Progressive Requirement for Multiple Therapies (UKPDS 49)</SUBTITLE>
Turner, R. C. (1999) · JAMA · doi:10.1001/jama.281.21.2005 · Cited by 2,375
Untitled work
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
Fat Accumulation in the Liver Is Associated with Defects in Insulin Suppression of Glucose Production and Serum Free Fatty Acids Independent of Obesity in Normal Men
Seppala-Lindroos, A. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.7.3023 · Cited by 168
Self-citation
Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., DeFronzo, R. A., EINHORN, D. F., Fonseca, V. A., et al. (2016) · Endocrine Practice · doi:10.4158/ep151126.cs · Cited by 879
“Premixed insulins provide less dosing flexibility and have been associated with a higher frequency of hypoglycemic events compared to basal and basal-bolus regimens (128-130).”
Background
Insulin analogues
Hirsch, I. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040832 · Cited by 667
American Association of Clinical Endocrinologists and American College of Endocrinology – Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan – 2015 — Executive Summary
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G. E., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S. E., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.gl · Cited by 646
Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary
Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2019-0472 · Cited by 598
American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015
Handelsman, Y., Bloomgarden, Z. T., Grunberger, G., Umpierrez, G., Zimmerman, R. S., Bailey, T. S., Blonde, L., Bray, G. A., Cohen, A. J., Dagogo-Jack, S., et al. (2015) · Endocrine Practice · doi:10.4158/ep15672.glsuppl · Cited by 559
Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review
DeWitt, D. E., & Hirsch, I. B. (2003) · JAMA · doi:10.1001/jama.289.17.2254 · Cited by 502
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., DeFronzo, R. A., EINHORN, D. F., Fonseca, V. A., et al. (2018) · Endocrine Practice · doi:10.4158/cs-2017-0153 · Cited by 503
Hypoglycaemia in Type 2 diabetes
Amiel, S. A., Dixon, T., Mann, R., & Jameson, K. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02341.x · Cited by 472
Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients.
Ryysy, L., Häkkinen, A. M., Goto, T., Vehkavaara, S., Westerbacka, J., Halavaara, J., & Yki-Järvinen, H. (2000) · Diabetes · doi:10.2337/diabetes.49.5.749 · Cited by 431
“In 2 of our previous studies, each of which lasted 1 year, the bedtime insulin dose required to achieve reasonable glycemic control varied 20-fold, from 8 to 170 U/day (1,3).”
BackgroundSelf-citation
Comparison of Bedtime Insulin Regimens in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial
Yki-Järvinen, H., Ryysy, L., Nikkilä, K., Tulokas, T., Vanamo, R., & Heikkilä, M. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-5-199903020-00002 · Cited by 433
“Glycemic control was better maintained in this study than in our first multicenter study (6, 7).”
BackgroundResultInfluentialSelf-citation
Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm – 2017 executive summary
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2017) · Endocrine Practice · doi:10.4158/ep161682.cs · Cited by 435
“Premixed insulins provide less dosing flexibility and have been associated with a higher frequency of hypoglycemic events compared to basal and basal-bolus regimens (140-142).”
Background
Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes
Janka, H. U., Plewe, G., Riddle, M. C., Kliebe-Frisch, C., Schweitzer, M. A., & Yki-Järvinen, H. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.254 · Cited by 414
Self-citation
1998 clinical practice guidelines for the management of diabetes in Canada
Meltzer, S. J., Leiter, L. A., Daneman, D., Gerstein, H. C., Lau, D. C. W., Ludwig, S. M., Yale, J., Zinman, B., Lillie, D., & Steering, C. (1998) · Canadian Medical Association Journal · Cited by 378
Glimepiride Combined with Morning Insulin Glargine, Bedtime Neutral Protamine Hagedorn Insulin, or Bedtime Insulin Glargine in Patients with Type 2 Diabetes
Fritsche, A., Schweitzer, M. A., H�ring, H.-U., & and the 4001 Study Group* (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-12-200306170-00006 · Cited by 331
“Combination therapy with oral antidiabetic drugs and bedtime neutral protamine Hagedorn (NPH) insulin has proven to be as effective as other, more complex insulin regimens and is associated with less weight gain (11, 12).”
Background
Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus
Mäkimattila, S., Nikkilä, K., & Yki‐Järvinen, H. (1999) · Diabetologia · doi:10.1007/s001250051172 · Cited by 314
“In the FINMIS study, weight gain in the 100 patients followed for 1 year was positively correlated with statistically significant increases in blood pressure and LDL cholesterol [3, 10].”
Self-citation
Combination therapies with insulin in type 2 diabetes
Yki-Järvinen, H. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.758 · Cited by 300
“BLOOD PRESSURE Regarding blood pressure, in a follow-up study of the patients participating in the FINMIS study (15,30), blood pressure increased significantly in the entire group of 100 patients during 1 year.”
BackgroundMethodInfluential
I Diretriz Brasileira de Diagnóstico e Tratamento da Síndrome Metabólica
de Carvalho, M. H. C., Mancini, M. C., de Melo, M. E., Bahia, L., Negrão, C. E., de Matos, L. D. N. J., Sanjuliani, A. F., Kohlmann, O., Oliveira, J. E. P. D., Lerário, A. C., et al. (2005) · Arquivos Brasileiros de Cardiologia · doi:10.1590/s0066-782x2005000700001 · Cited by 305
Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2019 executive summary.
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S., DeFronzo, R. A., Einhorn, D., Fonseca, V. A., et al. (2019) · Endocrine Practice · doi:10.4158/cs-2018-0535 · Cited by 297
“Premixed insulins provide less dosing flexibility and have been associated with a higher frequency of hypoglycemic events compared to basal and basal-bolus regimens (260-262).”
Background
American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement - Executive Summary
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garvey, W. T., et al. (2013) · Endocrine Practice · doi:10.4158/ep13176.cs · Cited by 282
Symptoms and Well-Being in Relation to Glycemic Control in Type II Diabetes
Van der Does, F. E. E., De Neeling, J. N. D., Snoek, F. J., Kostense, P. J., Grootenhuis, P. A., Bouter, L. M., & Heine, R. J. (1996) · Diabetes Care · doi:10.2337/diacare.19.3.204 · Cited by 262
“This improvement may be attributed to the accompanying education and treatment satisfaction: the majority of patients find insulin therapy easier than expected (5,6).”
Background
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults
Lipscombe, L. L., Booth, G. L., Butalia, S., Dasgupta, K., Eurich, D. T., Goldenberg, R., Khan, N., MacCallum, L., Shah, B. R., & Simpson, S. H. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.034 · Cited by 261
“The addition of bedtime insulin to metformin therapy leads to less weight gain than insulin plus a sulfonylurea or twice-daily NPH insulin (85).”
Influential
Insulin Resistance Implications for Type II Diabetes Mellitus and Coronary Heart Disease
Haffner, S. M., & Miettinen, H. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00027-2 · Cited by 227
The Effects of Improved Glycemic Control on Complications in Type 2 Diabetes
Gaster, B., & Hirsch, I. B. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.2.134 · Cited by 229
American Association of Clinical Endocrinologists’ Comprehensive Diabetes Management Algorithm 2013 Consensus Statement
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garvey, W. T., et al. (2013) · Endocrine Practice · doi:10.4158/ep13176.csuppl · Cited by 219
Insulin therapy for type 2 diabetes.
Swinnen, S. G., Hoekstra, J. B., & DeVries, J. H. (2009) · Diabetes Care · doi:10.2337/dc09-s318 · Cited by 181
Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in Type 1 and Type 2 diabetic patients
Boehm, B. O., Home, P., Behrend, C., Kamp, N., & Olinder, A. L. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00733.x · Cited by 176
Drug Treatment of Non-Insulin-Dependent Diabetes Mellitus in the 1990s
Scheen, A. J. (1997) · Drugs · doi:10.2165/00003495-199754030-00001 · Cited by 173
Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group
Saudek, C. D. (1996) · JAMA · doi:10.1001/jama.276.16.1322 · Cited by 152
Weight management in patients with type 1 diabetes and obesity
Mottalib, A., Kasetty, M., Mar, J. Y., Elseaidy, T., Ashrafzadeh, S., & Hamdy, O. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0918-8 · Cited by 149
Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review
Leslie, W. S., Hankey, C. R., & Lean, M. E. J. (2007) · QJM · doi:10.1093/qjmed/hcm044 · Cited by 173
Efficacy of Insulin and Sulfonylurea Combination Therapy in Type II Diabetes
Johnson, J. L. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440030049007 · Cited by 145
Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes
Juurinen, L., Tiikkainen, M., Häkkinen, A.-M., Hakkarainen, A., & Yki-Järvinen, H. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00133.2006 · Cited by 141
“We have, however, previously measured diurnal insulin profiles before and during basal insulin therapy (48) and shown that insulin therapy does induce hyperinsulinemia, which in turn would be expected to stimulate rather than inhibit lipogenesis in the liver.”
BackgroundSelf-citation
Initiate Insulin by Aggressive Titration and Education (INITIATE)
Yki-Järvinen, H., Juurinen, L., Alvarsson, M., Bystedt, T., Caldwell, I., Davies, M., Lahdenperä, S., Nijpels, G., & Vähätalo, M. (2007) · Diabetes Care · doi:10.2337/dc06-1357 · Cited by 139
“We have previously shown that treatment satisfaction improved with combination therapy compared with use of continued oral agents (7), suggesting that improved glycemic control rather than simply participating in a study improves general wellbeing.”
Background
Pharmacologic management of type 2 diabetes
Harper, W., Clement, M., Goldenberg, R., Hanna, A., Main, A., Retnakaran, R., Sherifali, D., Woo, V., & Yale, J.-F. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.021 · Cited by 138
Bodyweight Change as an Adverse Effect of Drug Treatment
Pijl, H., & Meinders, A. E. (1996) · Drug Safety · doi:10.2165/00002018-199614050-00005 · Cited by 138
Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patients
Wainstein, J., Metzger, M., Boaz, M., Minuchin, O., Cohen, Y., Yaffe, A. E., Yerushalmy, Y., Raz, I., & Harman‐Boehm, I. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01597.x · Cited by 136
Diabetes medications and body weight
Mitri, J., & Hamdy, O. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903081725 · Cited by 134
“Similarly, detemir insulin induced less weight gain in comparison to NPH insulin after 24 weeks of intervention [77].”
BackgroundResult
Sustained good glycaemic control in NIDDM patients by implementation of structured care in general practice: 2-year follow-up study
de Sonnaville, J. J. J., Bouma, M., Colly, L. P., Devillé, W. L. J. M., WIJKEL, D., & Heine, R. J. (1997) · Diabetologia · doi:10.1007/s001250050829 · Cited by 135
“The combination of insulin at bedtime with sulphonylurea drugs, as advocated in NIDDM [ 24-26 ], followed by J. J. J. de Sonnaville et al.: Structured care for NIDDM patients”
Background
INSULIN THERAPY IN TYPE 2 DIABETES
Mudaliar, S. R., & Edelman, S. V. (2001) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70222-x · Cited by 130
“In one of the first large studies demonstrating the efficacy of insulin/ sulfonylurea combination therapy, Yki-Jarvinen et al [ 38 ] compared combination therapy with regimens of two and four insulin injections per day in patients with type 2 diabetes.”
BackgroundInfluential
The Role of Acarbose in the Treatment of Non–Insulin-Dependent Diabetes Mellitus
Hanefeld, M. (1998) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(97)00123-2 · Cited by 129
DURAbility of Basal Versus Lispro Mix 75/25 Insulin Efficacy (DURABLE) Trial 24-Week Results
Buse, J. B., Wolffenbuttel, B. H. R., Herman, W. H., Shemonsky, N. K., Jiang, H. H., Fahrbach, J. L., Scism-Bacon, J. L., & Martin, S. (2009) · Diabetes Care · doi:10.2337/dc08-2117 · Cited by 131
Longitudinal study on glycaemic control and quality of life in patients with Type 2 diabetes mellitus referred for intensified control
Goddijn, P. P. M., Bilo, H. J. G., Feskens, E. J. M., Groenier, K. H., van der Zee, K. I., & Jong, B. M. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00002.x · Cited by 120
A Summary of the ADVANCE Trial
Heller, S. R., & on behalf of the ADVANCE Collaborative Group (2009) · Diabetes Care · doi:10.2337/dc09-s339 · Cited by 126
Effect of Obesity on the Response to Insulin Therapy in Noninsulin-Dependent Diabetes Mellitus
Yki‐Järvinen, H., Ryysy, L., Kauppila, M., Kujansuu, E., Lahti, J., Marjanen, T., NISKANEN, L. K., Rajala, S., Salo, S., Seppälä, P., et al. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4460 · Cited by 118
“As insulin concentrations are higher during multiple insulin injection than during combination therapy ( 2 ), it is possible that the tendency toward a greater fall of triglycerides during insulin than combination therapy was due to a greater stimulation of LPL by insulin.”
BackgroundMethodResultInfluentialSelf-citation
Screening, prevention, counseling, and treatment for the complications of type II diabetes mellitus
Vijan, S. S., Stevens, D. L., Herman, W. H., Funnell, M. M., & Standiford, C. J. (1997) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.1997.07111.x · Cited by 114
Starting patients with type 2 diabetes on insulin therapy using once-daily injections of biphasic insulin aspart 70/30, biphasic human insulin 70/30, or NPH insulin in combination with metformin
Kilo, C., Mezitis, N. H. E., Jain, R., Mersey, J. H., McGill, J. B., & Raskin, P. (2003) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(03)00076-x · Cited by 113
“more effective glycemic control than single insulin injections alone (Riddle et al., 1992; Riddle et al., 1989; Shank et al., 1995; Yki-Järvinen et al., 1992).”
Background
Weight Effect of Current and Experimental Drugs for Diabetes Mellitus
Purnell, J. Q., & Weyer, C. (2003) · Treatments in Endocrinology · doi:10.2165/00024677-200302010-00004 · Cited by 113
Health Care Costs and Medication Adherence Associated with Initiation of Insulin Pen Therapy in Medicaid-Enrolled Patients with Type 2 Diabetes: A Retrospective Database Analysis
Pawaskar, M. D., CAMACHO, F. T., Anderson, R. T., Cobden, D., Joshi, A. V., & Balkrishnan, R. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.007 · Cited by 111
Obesity and fat quantification in lean tissues using three-point Dixon MR imaging
Kovanlıkaya, A., Mittelman, S. D., Ward, A., Geffner, M. E., Dorey, F. J., & Gilsanz, V. (2005) · Pediatric Radiology · doi:10.1007/s00247-005-1413-y · Cited by 111
“Total cholesterol, HDL- and LDL-cholesterol and triglycerides were measured as previously described [ 17 ].”
Method
Pathophysiology of Type 2 Diabetes and Modes of Action of Therapeutic Interventions
Dagogo-Jack, S. (1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440370028004 · Cited by 111
Comparison of Insulin With or Without Continuation of Oral Hypoglycemic Agents in the Treatment of Secondary Failure in NIDDM Patients
Chow, C., Tsang, L. W. W., Sorensen, J. P., & Cockram, C. S. (1995) · Diabetes Care · doi:10.2337/diacare.18.3.307 · Cited by 110
“Similar findings, but to a lesser extent, are demonstrated by several recent studies using a parallel or crossover design and similar methodology that have compared combination therapy with insulin therapy (5,23-25).”
BackgroundResult
Management of non-insulin-dependent diabetes mellitus
Williams, G. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90822-2 · Cited by 106
Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus
Goudswaard, A. N., Furlong, N. J., Valk, G. D., Stolk, R. P., & Rutten, G. E. H. M. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003418.pub2 · Cited by 99
Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial
Aljabri, K., Kozak, S. E., & Thompson, D. M. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.07.023 · Cited by 97
Inhaled Insulin Provides Improved Glycemic Control in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Agents A Randomized Controlled Trial
Weiss, S. R. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.19.2277 · Cited by 98
SULFONYLUREAS
Zimmerman, B. R. (1997) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70264-4 · Cited by 99
Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes
Lebovitz, H. E. (2011) · Diabetes Care · doi:10.2337/dc11-s225 · Cited by 100
Obesity and cardiovascular risk factors in type 2 diabetes: results from the Swedish National Diabetes Register
Ridderstråle, M., Gudbjörnsdottir, S., Eliasson, B., Nilsson, P. M., & Cederholm, J. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01617.x · Cited by 95
Glycemic Management of Type 2 Diabetes: An Emerging Strategy with Oral Agents, Insulins, and Combinations
Riddle, M. C. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2004.12.002 · Cited by 94
“The last option, is simple, effective, and well-tolerated and causes the least weight gain [64].”
Background
Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus
Matthaei, S., Bierwirth, R., Fritsche, A., Gallwitz, B., Häring, H., Joost, H., Kellerer, M., Kloos, C., Kunt, T., Nauck, M. A., et al. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1239559 · Cited by 93
“Yki-J ä rvinen and associates ( Yki-J ä rvinen et al., 1992, EC Ib ) compared combination therapy with conventional and intensi ﬁ ed therapy with 153 type 2 diabetics in a 3 – month, randomised, controlled study, and were unable to ﬁ nd any advantages in any of the various insulin regimens with…”
Analysis of factors influencing pancreatic β-cell function in Japanese patients with type 2 diabetes: Association with body mass index and duration of diabetic exposure
Funakoshi, S., Fujimoto, S., Hamasaki, A., Fujiwara, H., Fujita, Y., Ikeda, K., Hamamoto, Y., Hosokawa, M., Seino, Y., & Inagaki, N. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.09.010 · Cited by 89
Weight Beneficial Treatments for Type 2 Diabetes
Meneghini, L. F., Orozco‐Beltrán, D., Khunti, K., Caputo, S., Damçi, T., Liebl, A., & Ross, S. A. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1074 · Cited by 82
Rationale and options for combination therapy in the treatment of Type 2 diabetes
Gaal, L. V., & Leeuw, I. D. (2003) · Diabetologia · doi:10.1007/s00125-002-0936-0 · Cited by 82
“One study has reported that bedtime or morning insulin induces less weight gain and hyperinsulinaemia than multiple injections, while achieving the same level of glycaemic control [23].”
Background
Targeting postprandial hyperglycemia
Rendell, M., & Jovanovič, L. (2006) · Metabolism · doi:10.1016/j.metabol.2006.05.012 · Cited by 80
“The addition of basal insulin supplementation is very effective in reducing HbA1c when combinations of oral hypoglycemic agents no longer adequately maintain levels [261-263].”
Background
Glycemic control in diabetes mellitus: have changes in therapy made a difference?
Nathan, D. M., McKitrick, C., Larkin, M., Schaffran, R., & Singer, D. E. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)89453-3 · Cited by 79
Insulin Glargine
McKeage, K., & Goa, K. L. (2001) · Drugs · doi:10.2165/00003495-200161110-00007 · Cited by 78
“In type 1 disease this will include full replacement therapy whereas patients with type 2 disease may benefit more from a simple regimen of bedtime insulin plus an oral antidiabetic agent.[11] The pharmacokinetics and pharmacodynamics of traditional insulins have not achieved the basal and prandial levels required for…”
Management of patients on chronic glucocorticoid therapy: an endocrine perspective
Trence, D. (2003) · Primary Care Clinics in Office Practice · doi:10.1016/s0095-4543(03)00038-1 · Cited by 74
“The use of bedtime intermediate-acting insulin is preferred to pre-dinner dosing due to a lower risk of nocturnal hypoglycemia [15,16]; however, if a glucose level greater than 300 mg/dL persists that is not amenable to an increase in pre-dinner insulin dosing, a supplement dose of 0.”
Background
Combining insulin and oral agents
Buse, J. B. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00339-9 · Cited by 70
Pulmonary Insulin Administration Using the AERx® System: Physiological and Physicochemical Factors Influencing Insulin Effectiveness in Healthy Fasting Subjects
Farr, S. J., McElduff, A., Mather, L. E., Okikawa, J. K., Ward, M., Gonda, I., Ličko, V., & Rubsamen, R. (2000) · Diabetes Technology & Therapeutics · doi:10.1089/15209150050025131 · Cited by 72
Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVETM study
Dornhorst, A., Lüddeke, H.-J., Sreenan, S., Kozlovski, P., Hansen, J. B., Looij, B. J., Meneghini, L., & on behalf of the PREDICTIVE Study Group (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01715.x · Cited by 71
Timely initiation of basal insulin
Riddle, M. C. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.12.003 · Cited by 71
Insulin improves well-being for selected elderly type 2 diabetic subjects
Reza, M., Taylor, C., Towse, K., Ward, J. D., & Hendra, T. J. (2002) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(01)00327-8 · Cited by 68
Response to Intensive Therapy Steps and to Glipizide Dose in Combination With Insulin in Type 2 Diabetes: VA feasibility study on glycemic control and complications (VA CSDM)
Abraira, C., Henderson, W. G., Colwell, J. A., Nuttall, F. Q., Comstock, J. P., Emanuele, N., Levin, S. R., Sawin, C. T., Silbert, C. K., & VA CSDM Group (1998) · Diabetes Care · doi:10.2337/diacare.21.4.574 · Cited by 65
“When multiple daily injections were used in other studies as initial treatment in type 2 diabetes, aside from the added inconvenience, there was substantial weight gain (13,18).”
BackgroundMethod
IMPORTANCE OF GLUCOSE CONTROL
Edelman, S. V. (1998) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70019-5 · Cited by 65
Diabetes in Old Age
Sinclair, A. J. (2010) · Wiley eBooks · doi:10.1002/9781444324808.ch54 · Cited by 64
Utility of indices using C-peptide levels for indication of insulin therapy to achieve good glycemic control in Japanese patients with type 2 diabetes
Funakoshi, S., Fujimoto, S., Hamasaki, A., Fujiwara, H., Fujita, Y., Ikeda, K., Takahara, S., Nagashima, K., Hosokawa, M., Seino, Y., et al. (2011) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00096.x · Cited by 64
Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update
Hanefeld, M., Fleischmann, H., Siegmund, T., & Seufert, J. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00855-5 · Cited by 68
Comparison of Different Insulin Regimens in Elderly Patients With NIDDM
Wolffenbuttel, B. H. R., Sels, J.-P. J. E., Rondas-Colbers, G. J., Menheere, P. P. C. A., & Kruseman, A. C. N. (1996) · Diabetes Care · doi:10.2337/diacare.19.12.1326 · Cited by 58
“6) 532 (136-2,217) 24 (10-499) 20(11-589) 6.”
BackgroundResultInfluential
Increased epinephrine and skeletal muscle responses to hypoglycemia in non-insulin-dependent diabetes mellitus.
Shamoon, H., Friedman, S., Canton, C., Zacharowicz, L., Hu, M., & Rossetti, L. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117267 · Cited by 57
“Onthe other hand, when insulin is required for treatment of NIDDM, the doses are generally high and in the range of values capable of suppressing hepatic glucose output (HGO) (4).”
Background
A review of the effects of antihyperglycaemic agents on body weight: the potential of incretin targeted therapies
Barnett, A. H., Allsworth, J., Jameson, K., & Mann, R. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x199691 · Cited by 57
Rosiglitazone Reduces Liver Fat and Insulin Requirements and Improves Hepatic Insulin Sensitivity and Glycemic Control in Patients with Type 2 Diabetes Requiring High Insulin Doses
Juurinen, L., Kotronen, A., Granér, M., & Yki‐Järvinen, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1825 · Cited by 57
Self-citation
The management of the obese diabetic patient
Albu, J., & Raja-Khan, N. T. (2003) · Primary Care Clinics in Office Practice · doi:10.1016/s0095-4543(03)00043-5 · Cited by 56
“The adverse effects and potential risks of intensive insulin treatment included weight gain, which was directly associated with increased hyperinsulinemia [18,63–65].”
Background
TREATMENT OF TYPE 2 DIABETES MELLITUS
Feinglos, M. N., & Bethel, M. A. (1998) · Medical Clinics of North America · doi:10.1016/s0025-7125(05)70023-7 · Cited by 56
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2015 Executive Summary
Garber, A. J., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bloomgarden, Z. T., Bush, M. A., Dagogo-Jack, S. E., Davidson, M., EINHORN, D. F., Garber, J. R., et al. (2015) · Endocrine Practice · doi:10.4158/ep151063.cs · Cited by 55
Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double‐blind and cross‐over trial
Perriello, G., Pampanelli, S., Porcellati, F., Avogaro, A., Bosi, E., Petrella, G., Squatrito, S., Furneri, S., Marra, G., Vitali, L., et al. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01473.x · Cited by 54
Glucose Control and Insulin Resistance in Non-Insulin-dependent Diabetes Mellitus
Robert, H. R. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-1_part_2-199601011-00004 · Cited by 54
A review of basal insulins
Barnett, A. H. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00996.x · Cited by 52
A Prospective Trial of U500 Insulin Delivered by Omnipod in Patients With Type 2 Diabetes Mellitus and Severe Insulin Resistance
Lane, W. S., Weinrib, S. L., Rappaport, J. M., & Przestrzelski, T. (2010) · Endocrine Practice · doi:10.4158/ep10014.or · Cited by 51
Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control
Vos, R. C., van Avendonk, M. J., Jansen, H., Goudswaard, A. N. N., van den Donk, M., Gorter, K. J., Kerssen, A., & Rutten, G. E. H. M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006992.pub2 · Cited by 54
Metabolic evolution of type 2 diabetes: a 10‐year follow‐up from the time of diagnosis
NISKANEN, L. K., Karjalainen, J., Siitonen, O., & Uusitupa, M. I. J. (1994) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1994.tb00794.x · Cited by 51
Self-citation
Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failure
Bastyr, E. J., Johnson, M. E., TRAUTMANN, M. E., Anderson, J. H., & Vignati, L. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(99)80049-6 · Cited by 47
Randomized Study of Two Different Target Levels of Glycemic Control Within the Acceptable Range in Type 2 Diabetes: Effects on well-being at 1 year
Does, F. E. E. V. D., de Neeling, J. N. D., Snoek, F. J., Grootenhuis, P. A., Kostense, P. J., Bouter, L. M., & Heine, R. J. (1998) · Diabetes Care · doi:10.2337/diacare.21.12.2085 · Cited by 44
Six-month multicentric, open-label, randomized trial of twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11)
Hirao, K., Arai, K., Yamauchi, M., Takagi, H., & Kobayashi, M. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.08.011 · Cited by 44
Improvement of Glycemic Control by Re-education in Insulin Injection Technique in Patients with Diabetes Mellitus
Nakatani, Y., Matsumura, M., Monden, T., Aso, Y., & Nakamoto, T. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0066-8 · Cited by 42

Authors: Yki-Järvinen, H., Kauppila, M., Kujansuu, E., Lahti, J., Marjanen, T., Niskanen, L., Rajala, S., Ryysy, L., Salo, S., Seppälä, P., Tulokas, T., Viikari, J., Karjalainen, J., & Taskinen, M.-R.
Affiliations: University of Turku (FI)
Hatanpää Hospital (FI)
Kuopio University Hospital (FI)
Kymenlaakson keskussairaala (FI)
Lapland Central Hospital (FI)
University of Oulu (FI)
University of Helsinki (FI)
ORCID: Kujansuu, Eila
Niskanen, Leo
Viikari, Jorma
Taskinen, Marja-Riitta
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1992-11-12
Volume: 327
Issue: 20
Pages: 1426-1433
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm199211123272005
OpenAlex: W1964413807
Cited by: 324
References: 29
Citations by year: 2024: 1 · 2023: 3 · 2022: 4 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 7 · 2017: 9 · 2016: 5 · 2015: 7 · 2014: 5 · 2013: 12 · 2012: 8
FWCI: 6.09
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: type 2 diabetes, insulin regimens, NPH insulin, regular insulin, oral antidiabetic drugs, glycemic control, HbA1c, weight gain, subjective well-being, insulin therapy comparison, combination therapy, multiple daily insulin injections
MeSH terms: Administration, Oral, Adult, Aged, Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 2, Drug Administration Schedule, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Intravenous, Insulin, Lipoproteins, Male, Middle Aged, Monitoring, Physiologic, Patient Acceptance of Health Care, Weight Gain

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Comparison of Insulin Regimens in Patients with Non-Insulin-Dependent Diabetes Mellitus

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks